Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 7/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | QDPR | P09417 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2377686 | 0.86 | EPHX2 (0.37) | EPHX2EPHX1CYP1A2TDP1KDM4E | |
| SCHEMBL16169058 | 0.86 | EPHX2 (0.37) | EPHX2EPHX1CYP1A2TDP1KDM4E | |
| SCHEMBL21325280 | 0.84 | CYP1A2 (0.50) | EPHX2EPHX1CYP1A2TDP1KDM4E | |
| SCHEMBL90563 | 0.78 | CYP1A2 (0.48) | EPHX2EPHX1CYP1A2TDP1KDM4E | |
| SCHEMBL2376108 | 0.76 | HPGD (0.54) | EPHX1KDM4ESMN1; SMN2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL1132378 | 0.76 | GNAI3 (0.50) | EPHX2EPHX1CYP1A2TDP1KDM4E | |
| SCHEMBL27183 | 0.75 | ALDH1A1 (0.56) | EPHX2EPHX1CYP1A2TDP1KDM4E | |
| SCHEMBL83783 | 0.75 | CYP1A2 (0.50) | EPHX2EPHX1CYP1A2TDP1KDM4E | |
| Hydrochloric Acid SCHEMBL16397180 | 0.74 | GNAI3 (0.49) | EPHX2EPHX1CYP1A2TDP1KDM4E | |
| SCHEMBL6631486 | 0.74 | EPHX2 (0.40) | EPHX2EPHX1CYP1A2TDP1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8012974-B2 | Pyrrolopyrazinyl urea kinase inhibitors | ROCHE PALO ALTO LLC (US) | 2011-09-06 | — | — | US | disclosed |
| US-20100144745-A1 | Pyrrolopyrazinyl Urea Kinase Inhibitors | ROCHE PALO ALTO LLC | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144745-A1 | Pyrrolopyrazinyl Urea Kinase Inhibitors | JAK1, JAK3, ULK3 | EPHX2 3904/4885EPHX1 3678/4885CYP1A2 2869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.